StreetInsider.com News Articles

Form 4/A Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R

Fri, 28 Aug 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260828/26999408.html

Form 4/A Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R

Fri, 28 Aug 2026 20:18:00 -0400

si-local-file:///var/storage/secattach/20260828/26999408.html

Form 4/A Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond

Fri, 28 Aug 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26999371.html

Form 4/A Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond

Fri, 28 Aug 2026 19:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26999371.html

Form 4 Monopar Therapeutics For: Aug 26 Filed by: RIOUX PATRICE

Thu, 27 Aug 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260827/26991690.html

Form 4 Monopar Therapeutics For: Aug 26 Filed by: RIOUX PATRICE

Thu, 27 Aug 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260827/26991690.html

Form 4 Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond

Thu, 27 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991577.html

Form 4 Monopar Therapeutics For: Aug 25 Filed by: Anderson Raymond

Thu, 27 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991577.html

Form 4 Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R

Thu, 27 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991578.html

Form 4 Monopar Therapeutics For: Aug 26 Filed by: Tsuchimoto Kim R

Thu, 27 Aug 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260827/26991578.html

Form 144 Monopar Therapeutics Filed by: RIOUX PATRICE

Wed, 26 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26982099.html

Form 144 Monopar Therapeutics Filed by: RIOUX PATRICE

Wed, 26 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26982099.html

Form 144 Monopar Therapeutics Filed by: Tsuchimoto Kim R

Wed, 26 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260826/26982064.html

Form 144 Monopar Therapeutics Filed by: Tsuchimoto Kim R

Wed, 26 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260826/26982064.html

Form 144 Monopar Therapeutics Filed by: Anderson Raymond

Tue, 25 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260825/26975347.html

Form 144 Monopar Therapeutics Filed by: Anderson Raymond

Tue, 25 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260825/26975347.html

Monopar names medical affairs chief, gets two AASLD presentations

Wed, 19 Aug 2026 08:00:19 -0400

Monopar Therapeutics Inc. (Nasdaq: MNPR) has appointed Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, effective September 1, 2026, according to a company statement.

Dr. Kent brings more than 20 years of biopharmaceutical experience in medical affairs, clinical development, and regulatory strategy. He most recently served as Chief Medical Officer of Sling Therapeutics. Before that, he spent more than a decade at Horizon Therapeutics, where he held the role of Executive Vice President, Medical Affairs, and helped lead efforts including the TEPEZZA Biologics License Application and its FDA Advisory Committee meeting. Earlier in his career, he

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

Wed, 19 Aug 2026 08:00:00 -0400

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting^® 2026, taking place November

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

Wed, 19 Aug 2026 08:00:00 -0400

Monopar Therapeutics (MNPR) PT Raised to $130 at Morgan Stanley

Mon, 17 Aug 2026 08:58:41 -0400

Morgan Stanley analyst Maxwell Skor raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $130.00 (from $115.00) while maintaining a Overweight rating.

Monopar Therapeutics (MNPR) PT Raised to $128 at Barclays

Thu, 13 Aug 2026 05:38:39 -0400

Barclays analyst Etzer Darout raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $128.00 (from $125.00) while maintaining a Overweight rating.

Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral

Thu, 13 Aug 2026 04:24:52 -0400

Cantor Fitzgerald analyst Kirsten Kluska downgraded Monopar Therapeutics (NASDAQ: MNPR) from Overweight to Neutral with a price target of $119.00 (from $109.00).

The analyst comments: “We are downgrading MNPR to Neutral with a PT of $119 vs. $109 (see below). Monopar reported 2Q26 earnings, with the key update being timelines around ALXN1840 (tiomolybdate choline) for Wilson disease (genetic disorder of copper buildup). Recall, the rolling NDA submission recently started and Monopar newly guided it could be completed within the next few months. Cash of $134.3M is guided to support operations through at least 12/31/27.

We like Monopar and ultimately believe that ALXN1840

Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral

Thu, 13 Aug 2026 04:24:52 -0400

Cantor Fitzgerald analyst Kirsten Kluska downgraded Monopar Therapeutics (NASDAQ: MNPR) from Overweight to Neutral with a price target of $119.00 (from $109.00).

We like Monopar and ultimately believe that ALXN1840

Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Saturn V Capital Management LP

Wed, 12 Aug 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260812/26914654.html

Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Saturn V Capital Management LP

Wed, 12 Aug 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260812/26914654.html